Core Insights - GoPro reported a quarterly loss of $0.09 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.03, marking an earnings surprise of -200.00% [1] - The company's revenues for the quarter ended September 2025 were $162.92 million, exceeding the Zacks Consensus Estimate by 0.51%, but down from $258.9 million year-over-year [2] - GoPro's stock has increased by approximately 62.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.6% [3] Financial Performance - Over the last four quarters, GoPro has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $229.9 million, while for the current fiscal year, the estimate is -$0.14 on revenues of $678.94 million [7] Industry Context - GoPro operates within the Zacks Audio Video Production industry, which is currently ranked in the bottom 22% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of GoPro's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of GoPro's stock price movement will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for GoPro was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]

Core Viewpoint - Amphastar Pharmaceuticals reported quarterly earnings of $0.93 per share, exceeding the Zacks Consensus Estimate of $0.77 per share, but down from $0.96 per share a year ago, indicating a +20.78% earnings surprise [1][2] Financial Performance - The company achieved revenues of $191.84 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.96% and showing a slight increase from $191.21 million year-over-year [2] - Over the last four quarters, Amphastar has exceeded consensus EPS estimates three times and topped revenue estimates twice [2] Stock Performance - Amphastar shares have declined approximately 31.8% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The current Zacks Rank for Amphastar is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.96 on revenues of $195.8 million, and for the current fiscal year, it is $3.25 on revenues of $725.3 million [7] - The outlook for the Medical - Generic Drugs industry is favorable, ranking in the top 19% of over 250 Zacks industries, suggesting potential for outperformance [8]

Genpact (G) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +7.78%. A quarter ago, it was expected that this business process management services provider would post earnings of $0.85 per share when it actually produced earnings of $0.88, delivering a surprise of +3.53%.Over the last f ...

Core Viewpoint - AerSale Corporation reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.10 per share, representing a -60.00% earnings surprise [1] - The company posted revenues of $71.19 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 16.96% and down from $82.68 million year-over-year [2] Financial Performance - Over the last four quarters, AerSale has surpassed consensus EPS estimates two times [2] - The company had a previous quarter earnings expectation of $0.05 per share but reported $0.20, resulting in a +300% surprise [1] - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $97.22 million, and for the current fiscal year, it is $0.35 on revenues of $356.1 million [7] Stock Performance - AerSale shares have increased by approximately 15.1% since the beginning of the year, compared to the S&P 500's gain of 15.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Aerospace - Defense Equipment industry, to which AerSale belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact AerSale's stock performance [5]

Core Insights - Fidelity National Financial (FNF) reported quarterly earnings of $1.63 per share, exceeding the Zacks Consensus Estimate of $1.43 per share, and up from $1.3 per share a year ago [1][2] - The company achieved revenues of $4.03 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 13.54% and increasing from $3.6 billion year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +13.99%, while the previous quarter saw a surprise of -17.14% with actual earnings of $1.16 compared to an expectation of $1.4 [2] - Over the last four quarters, FNF has exceeded consensus EPS estimates two times and topped revenue estimates three times [2][3] Future Outlook - The company's stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [4] - Current consensus EPS estimate for the upcoming quarter is $1.45 on revenues of $3.61 billion, and for the current fiscal year, it is $4.83 on revenues of $13.62 billion [8] Industry Context - The Insurance - Multi line industry, to which FNF belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [6][7]

HireQuest, Inc. (HQI) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +71.43%. A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.15, delivering a surprise of +36.36%.Over the last four quarters, the company ...

Core Insights - Huntsman reported a quarterly loss of $0.03 per share, outperforming the Zacks Consensus Estimate of a loss of $0.13, marking an earnings surprise of +76.92% [1] - The company generated revenues of $1.46 billion for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 1.15%, although this represents a decline from $1.54 billion in the same quarter last year [2] - Huntsman shares have decreased by approximately 57.4% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.20 on revenues of $1.45 billion, and for the current fiscal year, it is -$0.66 on revenues of $5.76 billion [7] Industry Context - The Chemical - Diversified industry, to which Huntsman belongs, is currently ranked in the bottom 9% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Huntsman's stock performance [5]

Core Viewpoint - BGC Group reported quarterly earnings of $0.29 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, and showing an increase from $0.26 per share a year ago, indicating a positive earnings surprise of +3.57% [1][2] Financial Performance - The company achieved revenues of $736.85 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.09%, and up from $561.11 million in the same quarter last year [2] - Over the last four quarters, BGC Group has exceeded consensus revenue estimates four times [2] Stock Performance - BGC Group shares have increased by approximately 0.7% since the beginning of the year, in contrast to the S&P 500's gain of 15.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $734.4 million, and for the current fiscal year, it is $1.17 on revenues of $2.92 billion [7] - The trend of estimate revisions for BGC Group was mixed prior to the earnings release, which may change following the recent results [6] Industry Context - The Financial - Investment Bank industry, to which BGC Group belongs, is currently ranked in the top 10% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Novavax reported a quarterly loss of $0.62 per share, which was better than the Zacks Consensus Estimate of a loss of $1.08, representing an earnings surprise of +42.59% [1] - The company generated revenues of $70.45 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 77.85%, although this was a decline from $84.51 million in the same quarter last year [2] - Novavax has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Financial Performance - The earnings surprise of +42.59% indicates a significant improvement compared to the previous year's loss of $0.76 per share [1] - The company has shown a strong performance in revenue estimates, topping consensus expectations four times in the last four quarters [2] Stock Performance - Novavax shares have declined approximately 4.4% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The current Zacks Rank for Novavax is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.33 on revenues of $125.59 million, while for the current fiscal year, it is $2.23 on revenues of $1.07 billion [7] - The outlook for the Medical - Biomedical and Genetics industry, where Novavax operates, is currently in the top 41% of Zacks industries, indicating a favorable environment for potential stock performance [8]

Canadian Natural Resources (CNQ) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.81%. A quarter ago, it was expected that this oil and natural gas company would post earnings of $0.44 per share when it actually produced earnings of $0.51, delivering a surprise of +15.91%.Over the ...